Safety
Two patients in the placebo group experienced a thromboembolic event, while no such events were reported in the fibrinogen group (Table S5). The proportion of patients with severe morbidity requiring intensive care or resuscitation was similar in both groups (Table 2), and organ failure was rare (2 patients in each group had a SOFA score ≥ 3).